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Background: Heart failure with normal ejection fraction (HFNEF) has no definitive therapy. Some advocate a primary focus on comorbidities such 
as vascular disease, atrial fibrillation, hypertension, diabetes, and/or chronic kidney disease. However, few studies report adherence to evidence-
based treatment for these conditions in hospitalized HFNEF patients.
Methods: We compared 882 HFNEF (left ventricular ejection fraction (EF) ≥ 50% w/o known valvular disease) and 1,506 systolic heart failure 
patients (EF < 50%) in the Mid-Michigan GAP-HF study (Oct 2002-Jun 2004), a quality-improvement effort for inpatient heart failure care. Based on 
evidence available during GAP-HF, we evaluated discharge prescription/accepted contraindication for the following:
1) ACE/ARB: EF ≤ 40%, history of vascular disease, diabetes w/ other cardiovascular risk factors, and/or diabetes w/ chronic kidney disease
2) Beta blocker: EF ≤ 40%, hypertension w/ coronary artery disease and/or admission for acute coronary syndrome (ACS)
3) Aspirin: known vascular disease, ACS admission, and/or coronary revascularization
4) Statin: known vascular disease or ACS w/ LDL cholesterol ≥ 100 mg/dL, and/or coronary revascularization
5) Appropriate anticoagulation for atrial fibrillation
Results: 
Clinical factors HFNEF Systolic heart failure
Age (years) 73 ± 12* 71 ± 14
Female (%) 68* 44
Diabetes (%) 52* 46
Hypertension (%) 84* 79
Atrial fibrillation (%) 36 34
Creatinine (mg/dL) 1.8 ± 1.7 1.7 ± 1.4
HFNEF Systolic heart failure
Medication Indicated Received† Indicated Received†
ACE/ARB 66%* 80% 89% 78%
Beta blocker 53%* 72%* 91% 81%
Aspirin 69%* 54% 79% 58%
Statin 12% 45% 14% 41%
Anticoagulation/afib 36% 55% 34% 57%
* p < 0.05 for comparison with systolic heart failure
† percent of eligible patients who received/had appropriate contraindication
Conclusions: Many hospitalized HFNEF patients are not receiving evidence-based therapies for comorbid conditions at hospital discharge. Further 
study is needed to define the links between this finding and HFNEF outcomes.
